KemPharm, Inc. (NASDAQ:KMPH) major shareholder Delaware Street Capital Master purchased 325,888 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The stock was bought at an average cost of $3.27 per share, for a total transaction of $1,065,653.76. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Shares of KemPharm, Inc. (KMPH) traded up 5.97% during mid-day trading on Friday, reaching $3.55. The company’s stock had a trading volume of 109,924 shares. KemPharm, Inc. has a 12 month low of $2.45 and a 12 month high of $5.40. The firm’s market capitalization is $52.03 million. The company has a 50 day moving average of $3.06 and a 200-day moving average of $3.80.

KemPharm (NASDAQ:KMPH) last posted its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.19. Equities research analysts forecast that KemPharm, Inc. will post ($2.72) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “KemPharm, Inc. (KMPH) Major Shareholder Delaware Street Capital Master Acquires 325,888 Shares” was posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/15/kempharm-inc-kmph-major-shareholder-delaware-street-capital-master-acquires-325888-shares.html.

A number of large investors have recently bought and sold shares of KMPH. C WorldWide Group Holding A S lifted its holdings in KemPharm by 110.1% during the 2nd quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock worth $1,527,000 after buying an additional 200,000 shares in the last quarter. Victory Capital Management Inc. acquired a new position in KemPharm during the 1st quarter worth $647,000. Finally, Bank of New York Mellon Corp lifted its holdings in KemPharm by 17.6% during the 1st quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 3,414 shares in the last quarter. 40.01% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have weighed in on KMPH shares. Roth Capital started coverage on KemPharm in a research note on Wednesday, June 28th. They set a “buy” rating and a $8.00 target price on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $7.00 target price on shares of KemPharm in a research note on Monday. Oppenheimer Holdings, Inc. set a $13.00 target price on KemPharm and gave the company a “buy” rating in a research note on Thursday, August 10th. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 1st. Finally, Zacks Investment Research raised KemPharm from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $8.10.

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Insider Buying and Selling by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.